NovaBay Pharmaceuticals Stock Forecast, Price & News

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

Is NovaBay Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NovaBay Pharmaceuticals stock.
View analyst ratings for NovaBay Pharmaceuticals or view top-rated stocks.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 1,660,000 shares, a drop of 20.2% from the December 15th total of 2,080,000 shares. Based on an average daily trading volume, of 923,600 shares, the short-interest ratio is presently 1.8 days. Currently, 4.7% of the shares of the company are sold short.
View NovaBay Pharmaceuticals' Short Interest.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for NovaBay Pharmaceuticals.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 67.65% and a negative net margin of 96.77%.
View NovaBay Pharmaceuticals' earnings history.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals shares reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NBY?

1 brokers have issued 12-month price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $2.20 to $2.20. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $2.20 in the next twelve months. This suggests a possible upside of 633.3% from the stock's current price.
View analysts' price targets for NovaBay Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:

• Justin M. Hall, President, CEO, Director & General Counsel
• Andrew Jones, Chief Financial Officer & Treasurer

Who are some of NovaBay Pharmaceuticals' key competitors?

Some companies that are related to NovaBay Pharmaceuticals include NeuBase Therapeutics (NBSE), Marker Therapeutics (MRKR), Eledon Pharmaceuticals (ELDN), Synaptogenix (SNPX), Acasti Pharma (ACST), IntelGenx Technologies (IGXT), Clever Leaves (CLVR), Ocuphire Pharma (OCUP), Adial Pharmaceuticals (ADIL), Oragenics (OGEN), Gain Therapeutics (GANX), Cocrystal Pharma (COCP), Aravive (ARAV), Cumberland Pharmaceuticals (CPIX) and Addex Therapeutics (ADXN).
View all of NBY's competitors.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.30.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals has a market capitalization of $13.48 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11.03 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does NovaBay Pharmaceuticals have?

NovaBay Pharmaceuticals employs 24 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

Where are NovaBay Pharmaceuticals' headquarters?

NovaBay Pharmaceuticals is headquartered at 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at [email protected], or via fax at 510-474-1577.